Quincy Sous Senart

Researchers are evaluating methods to measure calcifications in native coronary arteries, which are important in heart disease. This non-randomized pilot study compares two imaging techniques: the 3DStent tool using rotational angiography and intracoronary intravascular ultrasound (IVUS). The goal is to assess how well each method quantifies coronary calcifications in patients with calcified coronary lesions. The study uses the 3DStent imaging technique performed with 200° rotational angiography at 30 frames per second while an angioplasty balloon is deflated in the target lesion before or after angioplasty. IVUS imaging is done using an Opticross™ catheter with a slow withdrawal speed and intracoronary nitrate injection. Both imaging methods are applied to the same lesions to compare their measurements. Participants are patients with angiographically calcified coronary lesions who can have the IVUS catheter pass through the lesion. Researchers measure the extent of calcification in degrees using 3DStent and IVUS on the first day of the study. Participants give informed consent and are monitored for safety and data collection. The study includes patients aged 18 and older and involves assessment of coronary lesions using these imaging techniques.

Researchers are evaluating the Polymer-Free Sirolimus Eluting Coronary Stent System called Vivo ISAR in patients with coronary artery stenosis. The study aims to collect clinical outcome data in real-world patients with coronary artery disease, following standard care procedures. The goal is to assess results and safety with a 12-month follow-up after treatment. Participants receive treatment using the Vivo ISAR stent device, which is designed to improve blood flow by widening narrowed coronary arteries in patients with symptomatic ischemic heart disease. The study involves patients undergoing percutaneous coronary intervention, with the Vivo ISAR stent used exclusively when stenting one or more vessels. During the study, participants will be monitored for clinical outcomes including the rate of target lesion failure within 12 months after the procedure. Researchers will collect relevant data on health status and treatment effects as part of routine clinical practice. The study is observational and follows patients over a year to evaluate the device's performance and safety in everyday medical care.

This research aims to assess how often diaphragmatic dysfunction occurs after non-intubated video-assisted thoracoscopic surgery (NIVATS). This single-center prospective longitudinal study focuses on patients undergoing this less invasive surgery approach, which is commonly used for wedge resections, pneumothorax repair, and pleural biopsies with or without talc pleurodesis for pleural effusion. The study is designed to contribute to understanding the outcomes of NIVATS, especially in patients with poor cardio-pulmonary function. Participants will undergo the NIVATS procedure, which is part of an Enhanced Recovery After Surgery (ERAS) pathway and is considered the least invasive thoracic surgical method. Evaluations will be performed during surgery and then at 2 hours and 24 hours after the surgery ends. Data from these assessments will be collected and recorded electronically by the physician for analysis. Throughout the study, participants will be monitored at three time points: during surgery, 2 hours after, and 24 hours after surgery. Researchers will measure diaphragmatic excursion to evaluate diaphragmatic function. This monitoring helps determine the incidence of diaphragmatic dysfunction following the procedure. Participation involves consenting adults undergoing the specific surgery and agreeing to follow-up assessments within the first day after surgery.

Researchers are conducting a Phase 3, multicenter, randomized controlled trial to compare two types of coronary stents and two dual antiplatelet therapy (DAPT) regimens in patients with coronary artery disease. The study evaluates the non-inferiority of the angiolite sirolimus-eluting stent versus the Xience everolimus-eluting stent family in preventing target lesion failure. It also compares the superiority of an abbreviated one-month DAPT regimen versus the standard 12-month DAPT regimen in reducing clinically relevant bleeding events. Both comparisons are assessed after 12 months of follow-up. Participants are randomly assigned in a 2x2 factorial design to receive either the angiolite stent or the Xience stent, followed by randomization to either a one-month course of DAPT (acetylsalicylic acid plus prasugrel or ticagrelor, then P2Y12 inhibitor alone up to 12 months) or the standard 12-month DAPT regimen. The choice of agents and duration may vary based on clinical characteristics such as acute or chronic coronary syndrome and the need for oral anticoagulation. The study is open-label regarding stent type and antiplatelet therapy. During the 12-month study period, participants undergo regular assessments for target lesion failure and bleeding events classified by the Bleeding Academic Research Consortium (BARC) criteria. Researchers monitor safety and effectiveness outcomes to determine rates of stent failure and bleeding complications. The trial includes adults aged 18 to 95 years with significant coronary artery stenosis suitable for stent implantation and requires informed consent and willingness to participate.

Researchers are collecting detailed information about adults who experience convulsive or non-convulsive status epilepticus, a serious condition involving prolonged or repeated seizures. This registry study records data on the circumstances of seizure onset, clinical features, treatments given before and during hospital care, diagnostic test results, and causes of the seizures. The study aims to track outcomes for these patients over time to better understand this condition and its management. Participants in this study are adults aged 18 years or older diagnosed with status epilepticus lasting 5 minutes or more, either as continuous seizures or repeated seizures without full recovery between them. Data collection involves standardized forms capturing demographic details, timing of seizures and treatments, EEG monitoring results, and other clinical information. The study includes follow-up assessments at ICU and hospital discharge, as well as at 90 days and one year after the seizure event. Throughout the study, researchers gather clinical findings, laboratory and EEG results, and treatment information from hospital and pre-hospital sources. They evaluate patient outcomes using measures like vital status and the Glasgow Outcome Scale at multiple time points, including up to one year after the seizure. This comprehensive data helps monitor recovery and long-term effects of status epilepticus in critically ill patients.

Researchers are studying iron metabolism in patients with advanced kidney failure who are undergoing hemodialysis. The study focuses on understanding how iron is absorbed, processed, eliminated, and stored in the body, as well as how it relates to calcium phosphate metabolism, liver function, and inflammation. The main goal is to track the changes in two important hormones, hepcidin and erythroferrone, which control iron metabolism but are not regularly tested in dialysis centers. Participants will have blood samples taken, with 15 mL collected to measure the levels of hepcidin and erythroferrone over time. This procedure helps researchers observe the evolution of these markers in relation to the participants' health conditions during hemodialysis. During the study, participants will be monitored for changes in these hormone levels over a five-year period. Researchers will evaluate how these markers connect to other bodily functions and inflammation. The study involves regular blood tests to gather this information and aims to improve understanding of iron metabolism in hemodialysis patients.

Researchers are investigating kidney cancer through the UroCCR project, a national registry and research network in France dedicated to renal cell carcinoma (RCC). This platform collects detailed clinical, imaging, biological, and patient-reported data on kidney cancer from over 21,000 cases across 58 centers. The study aims to improve understanding of RCC management by integrating multidisciplinary care data, biological samples, and linking with national health datasets to support translational research, clinical evaluation, and social science studies. The study compares two surgical treatments for kidney cancer: radical nephrectomy and partial nephrectomy, with the choice of surgery made according to surgeon judgment. It follows patients over long periods, monitoring outcomes and complications after surgery. This national collaboration includes digital tools like perioperative monitoring and machine learning models to predict recurrence and survival. The network also supports ancillary studies, including retrospective and prospective clinical trials, to advance personalized treatment strategies. Participants provide comprehensive data on their clinical status, treatments, and quality of life. Researchers assess complications at multiple time points: 3, 6, and 12 months post-surgery, then yearly for 5 years, and every 2 years for up to 10 years. The study evaluates real-world outcomes in kidney cancer care, linking clinical information with biological samples and national health data, while ensuring standardized procedures, ethical oversight, and high data quality through robust governance.

This research focuses on adolescents with very large body sizes, defined as heights greater than +3 standard deviations on updated French growth charts. Most cases are constitutional, meaning related to family height, and are not due to treatable medical conditions. The study aims to evaluate a surgical technique called tibial and femoral epiphysiodesis, which has been used in Northern Europe to limit growth by targeting growth plates near the knees. This approach is being considered as an alternative to hormonal treatments currently used in France, which often cause many side effects. The surgical procedure involves sterilizing the growth cartilage in the distal femur and proximal tibia under general anesthesia using X-ray guidance to ensure complete treatment of the growth zones. The operation lasts about one and a half hours and results in small scars around the knees, with post-operative care including dressings and splints to reduce pain and limit movement. This technique is being offered to families who request treatment to limit excessive height growth. Participants will undergo regular monitoring including measurements of final size, sitting height, and evaluations of any surgery or orthopedic adverse events within one month after surgery. Patient and parent satisfaction will be assessed over five years. The study involves careful assessment of growth parameters, radiological evaluation of growth plate persistence, and psychological evaluation to ensure suitability for treatment. The total follow-up includes long-term observation to assess treatment safety and effectiveness.